Bezlotoxumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Bezlotoxumab. Educational only — not medical advice.
Labeled uses
ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.
Source: FDA labeling via NIH DailyMed (set 8f479bfe…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.